David Siegel D, Oriol A, Rajnics P. et al. Updated results from ASPIRE and ENDEAVOR, randomised, open-label multicentre phase 3 studies of carfilzomib in patients with relapsed/refractory multiple myeloma (RRMM). EHA 2017, abstract P333.
Ernstig zieke coronapatiënt herstelt sneller met imatinib
jun 2021 | Leukemie, Pneumonie, Virale infecties